1-7 of 7
Christopher P. Fox
Close
Sort by
Journal Articles

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis

Edward Poynton, Emily Chernucha, James Day, Catherine Prodger, David Hopkins, Pallav Rakesh, Tess O’Neill, Nisha Thakrar, Ayse Akarca, Esraa Jamal, Ayesha Ali, Amy A. Kirkwood, Sabine Pomplun, Teresa Marafioti, Maria Calaminici, Paul Greaves, Sridhar Chaganti, Pam McKay, Jeffery Smith, Toby A. Eyre, Nicolas Martinez-Calle, Kate Cwynarski, Christopher P. Fox, Jessica Okosun
Journal: Blood Advances
Blood Adv (2024) 8 (7): 1772–1775.
https://doi.org/10.1182/bloodadvances.2023011426
Published: 2024
Includes: Supplemental data
Journal Articles

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience

Clinical Trials & Observations
Rohan Shotton, Rachel Broadbent, Alia Alchawaf, Mohamed Bakri Mohamed, Adam Gibb, Nicolás Martinez-Calle, Christopher P. Fox, Mark Bishton, Alexandra Pender, Mary Gleeson, David Cunningham, Andrew Davies, Sina Yadollahi, Toby A. Eyre, Graham Collins, Faouzi Djebbari, Shireen Kassam, Paula Garland, Emily Watts, Wendy Osborne, William Townsend, Rachael Pocock, Matthew J. Ahearne, Fiona Miall, Xin Wang, Kim M. Linton
Journal: Blood Advances
Blood Adv (2024) 8 (4): 878–888.
https://doi.org/10.1182/bloodadvances.2023011305
Published: 2024
Includes: Supplemental data
Journal Articles

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Clinical Trials & Observations
Michael Northend, William Wilson, Wendy Osborne, Christopher P. Fox, Andrew J. Davies, Dima El-Sharkawi, Elizabeth H. Phillips, Hau Wui Sim, Shalal Sadullah, Nimish Shah, Ying Ying Peng, Iman Qureshi, Juanah Addada, Rocio Figueroa Mora, Neil Phillips, Andrea Kuhnl, Elizabeth Davies, David Wrench, Pamela McKay, Indrani Karpha, Anna Cowley, Richard Karim, Sarah Challenor, Vikram Singh, Cathy Burton, Rebecca Auer, Chris Williams, Joel Cunningham, Angus Broom, Anita Arasaretnam, Claire Roddie, Tobias Menne, William Townsend
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2920–2926.
https://doi.org/10.1182/bloodadvances.2021005953
Published: 2022
Includes: Supplemental data
Journal Articles

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial

Clinical Trials & Observations
Christopher P. Fox, Ayesha S. Ali, Graham McIlroy, Steffi Thust, Nicolás Martinez-Calle, Aimee E. Jackson, Louise M. Hopkins, Catherine M. Thomas, Shireen Kassam, Josh Wright, Sridhar Chaganti, Jeffery Smith, Ian Chau, Dominic Culligan, Kim M. Linton, Graham P. Collins, Andrés J. M. Ferreri, David Lewis, Andrew J. Davies, Rod Johnson, Dorothee P. Auer, Kate Cwynarski
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4073–4082.
https://doi.org/10.1182/bloodadvances.2021004779
Published: 2021
Includes: Supplemental data
Journal Articles

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP

Clinical Trials & Observations
Toby A. Eyre, William Wilson, Amy A. Kirkwood, Julia Wolf, Catherine Hildyard, Hannah Plaschkes, John Griffith, Paul Fields, Arief Gunawan, Rebecca Oliver, Stephen Booth, Jaimal Kothari, Christopher P. Fox, Nicolas Martinez-Calle, Andrew McMillan, Mark Bishton, Graham P. Collins, Chris S. R. Hatton
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2229–2236.
https://doi.org/10.1182/bloodadvances.2021004286
Published: 2021
Includes: Supplemental data
Journal Articles

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery

Clinical Trials & Observations
Matthew R. Wilson, Toby A. Eyre, Nicolas Martinez-Calle, Matthew Ahearne, Katrina E. Parsons, Gavin Preston, Jahanzaib Khwaja, Jeremy Schofield, Johnathon Elliot, Almurtadha Mula Kh, Nimish Shah, Cheuk-Kie Cheung, Matthew A. Timmins, Thomas Creasey, Kim Linton, Jeffery Smith, Christopher P. Fox, Fiona Miall, Kate Cwynarski, Pamela McKay
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3586–3593.
https://doi.org/10.1182/bloodadvances.2020002421
Published: 2020
Includes: Supplemental data
Journal Articles

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Clinical Trials & Observations
Anthony R. Mato, Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, Paul M. Barr, Frederick Lansigan, Bruce D. Cheson, Arun K. Singavi, Maryam Sarraf Yazdy, Nirav N. Shah, John N. Allan, Erica B. Bhavsar, Joanna Rhodes, Kaitlin Kennard, Stephen J. Schuster, AnnaLynn M. Williams, Alan P. Skarbnik, Andre H. Goy, Julie M. Goodfriend, Colleen Dorsey, Catherine C. Coombs, Hande Tuncer, Chaitra S. Ujjani, Ryan Jacobs, Allison M. Winter, John M. Pagel, Neil Bailey, Anna Schuh, Mazyar Shadman, Andrea Sitlinger, Hanna Weissbrot, Sivraj Muralikrishnan, Andrew Zelenetz, Amy A. Kirkwood, Christopher P. Fox
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1568–1573.
https://doi.org/10.1182/bloodadvances.2019000180
Published: 2019